Citations

Clear

16281 citation(s) found for "Yu, David".

Impact of duration of dual anti-platelet therapy on risk of complications after stent-assisted coiling of unruptured aneurysms
Ringer, Andrew J. , Hanel, Ricardó A. , Baig, Ammad A. , Siddiqui, Adnan H. , Lopes, Demetrius K. , Barros, Guilherme , Bass, David I. , Levitt, Michael R. , Young, Christopher C. , Naylor, Ryan M. , Crowley, R. Webster , Serrone, Joseph C. , Kan, Peter , Binning, Mandy J., Veznedaroglu, Erol, Boulos, Alan S. , Lopes, Demetrius Klee , Kan, Peter , Tawk, Rabih G , Levitt, Michael R , Siddiqui, Adnan H , Hanel, Ricardo A , Lanzino, Giuseppe , Tawk, Rabih G.

Mayo Clinic

Journal of NeuroInterventional Surgery | August 13, 2024 | Volume: 17 | Issue: 9 | Pages: 956-960

10.1136/jnis-2024-021977 | PMID 39137967 Get It

Background The optimal duration for dual antiplatelet therapy (DAPT) after stent-assisted coiling (SAC) of intracranial aneurysms is unclear. Longer-term therapy may reduce thrombotic complications but increase the risk of bleeding complications. Methods A retrospective review of prospectively maintained data at 12 institutions was conducted on patients with unruptured intracranial aneurysms who underwent SAC between January 1, 2016 and December 31, 2020, and were followed ≥6 months postprocedure. The type and duration of DAPT, stent(s) used, outcome, length of follow-up, complication rates, and incidence of significant in-stent stenosis (ISS) were collected. Results Of 556 patients reviewed, 450 met all inclusion criteria. Nine patients treated with DAPT <29 days after SAC and 11 treated for 43–89 days were excluded from the final analysis as none completed their prescribed duration of treatment. Eighty patients received short-term DAPT. There were no significant differences in the rate of thrombotic complications during predefined periods of risk in the short, medium, or long-term treatment groups (1/80, 1.3%; 2/188, 1.1%; and 0/162, 0%, respectively). Similarly, no differences were found in the rate of hemorrhagic complications during period of risk in any group (0/80, 0%; 3/188, 1.6%; and 1/162, 0.6%, respectively). Longer duration DAPT did not reduce ISS risk in any group. Conclusions Continuing DAPT >42 days after SAC did not reduce the risk of thrombotic complications or in-stent stenosis, although the risk of additional hemorrhagic complications remained low. It may be reasonable to discontinue DAPT after 42 days following non-flow diverting SAC of unruptured intracranial aneurysms.
The seasonal distribution of immune thrombotic thrombocytopenic purpura is influenced by geography: Epidemiologic findings from a multi‐center analysis of 719 disease episodes
Jacobs, Jeremy W. , Stanek, C , Symeonidis, Argiris , Shih, Andrew W. , Gavriilaki, Eleni , Pavenski, Katerina , Moorehead, Amy , Mingot‐Castellano, María Eva , Daou, Laetitia , Arnold, Donald M. , Henrie, Ryan , Smith, Tyler , Sreenivasan, Gayatri , Siniard, Rance C. , Wallace, Lisa R., Duque, Miriam Andrea, Wu, Yanyun , Harrington, Thomas J., Byrnes, Diana M. , Bitsani, Aikaterini , Davis, Amanda K. , Robinson, Danielle H., Eichbaum, Quentin , Kaiafa, Georgia , Klapper, Ellen, Klein, Monica S., Kotsiou, Nikolaos , Lalayanni, Chrysavgi , Mandala, Evdokia , Alkhateb, Rahaf, Fortuny, Lisandro, Mellios, Zois, Papalexandri, Apostolia, Parsons, Meredith G , Wellard, Cameron , Jia, Shiyang , Powers, Amy, Webb, Christopher B. , Yates, Sean G. , Bouzid, Raïda , Coppo, Paul, Bloch, Evan M. , Adkins, Brian D. , Stanek, Caroline G , Booth, Garrett , Symeonidis, Argiris , Shih, Andrew W , Gavriilaki, Eleni , Moorehead, Amy , Peyvandi, Flora , Mancini, Ilaria , Raval, Jay S , Mingot-Castellano, Maria Eva , Crowe, Elizabeth P , Arnold, Donald M , Yamada, Chisa , Kotsiou, Nikolaos , Aldarweesh, Fatima , Schlueter, Annette J , Tormey, Christopher A , Wood, Erica M , Wheeler, Allison P , Yates, Sean G , Bloch, Evan M , Adkins, Brian David , Jacobs, Jeremy W , Parsons, Meredith G , Booth, Garrett S. , Allen, Elizabeth S. , Grossman, Brenda J. , Pavenski, Katerina , Peyvandi, Flora , Agosti, Pasquale , Stephens, Laura D. , Raval, Jay S. , Pai, Menaka , Marques, Marisa B. , Yamada, Chisa , Robinson, Danielle H. , Villalba, Cristina A. Figueroa , Juskewitch, Justin E. , Kapsali, Eleni , Perez-Alvarez, Ingrid , Aldarweesh, Fatima , Schlueter, Annette J. , Tormey, Christopher A. , Wheeler, Allison P. , Coppo, Paul

Mayo Clinic

American Journal of Hematology | August 13, 2024 | Volume: 99 | Issue: 11 | Pages: 2063-2074

10.1002/ajh.27458 | PMID 39136282 Get It

AbstractPrior studies have suggested that immune thrombotic thrombocytopenic purpura (iTTP) may display seasonal variation; however, methodologic limitations and sample sizes have diminished the ability to perform a rigorous assessment. This 5‐year retrospective study assessed the epidemiology of iTTP and determined whether it displays a seasonal pattern. Patients with both initial and relapsed iTTP (defined as a disintegrin and metalloprotease with thrombospondin type motifs 13 activity <10%) from 24 tertiary centers in Australia, Canada, France, Greece, Italy, Spain, and the US were included. Seasons were defined as: Northern Hemisphere—winter (December–February); spring (March–May); summer (June–August); autumn (September–November) and Southern Hemisphere—winter (June–August); spring (September–November); summer (December–February); autumn (March–May). Additional outcomes included the mean temperature in months with and without an iTTP episode at each site. A total of 583 patients experienced 719 iTTP episodes. The observed proportion of iTTP episodes during the winter was significantly greater than expected if equally distributed across seasons (28.5%, 205/719, 25.3%–31.9%; p = .03). Distance from the equator and mean temperature deviation both positively correlated with the proportion of iTTP episodes during winter. Acute iTTP episodes were associated with the winter season and colder temperatures, with a second peak during summer. Occurrence during winter was most pronounced at sites further from the equator and/or with greater annual temperature deviations. Understanding the etiologies underlying seasonal patterns of disease may assist in discovery and development of future preventative therapies and inform models for resource utilization.
Neuro-Ophthalmic Literature Review
Bellows, David A., Chen, John J. , Hung, Wei-Che , Vaphiades, Michael S., Chen, John J , Mak, Andrew C. Y. , McClelland, Collin M. , Verma, Rashmi , Zhang, Xiaojun

Mayo Clinic

Neuro-Ophthalmology | August 12, 2024 | Volume: 48 | Issue: 5 | Pages: 381-389

10.1080/01658107.2024.2384339 Get It

CYP3A4 Poor and Intermediate Metabolizers Have a Higher Rate of Steroid-Induced Intraocular Pressure Response
Wright, Jessica , Xu, Sarah Chao Ying , Wong, M , Melik, Razan M. El , Hodge, David O. , Sit, Arthur J. , Xu, Sarah C , Wong, Mitchell H , Hodge, David, Wright, Jessica A , El Melik, Razan M , Sit, Arthur J

Mayo Clinic

Journal of Glaucoma | August 12, 2024 | Volume: 34 | Issue: 2 | Pages: e9-e12

10.1097/ijg.0000000000002482 | PMID 39133066 Get It

Purpose: Evaluate the relationship between CYP3A4 phenotype, the gene encoding the enzyme that metabolizes exogenous steroids, and the rate of steroid-induced intraocular pressure (IOP) response. Materials and Methods: Lymphocyte-derived DNA sequencing of CYP3A4 from 10073 patients was completed using the PGRN-Seq assay. Subjects with CYP3A4 intermediate metabolizer or slower phenotypes were identified and compared with controls matched by age, race, and sex. All subjects had at least 3 eye exams with at least an exam while on topical/systemic/local steroid in any body location except the eye. Patients with pre-existing glaucoma or glaucoma suspects were excluded. Results: Of the 10,073 patients, there were 63 patients who had CYP3A4 poor or intermediate metabolizer phenotype. Of the 63 patients, 22 had documented steroid use. Fifty-nine percent (13/22) of patients with CYP3A4 poor/intermediate metabolizer had a steroid-induced IOP response of 3 mm Hg or more, significantly higher compared with 23% (5/22) of matched controls (P=0.031). Although more poor/intermediate metabolizers were steroid responders, the average IOP elevation in steroid responders in both groups was similar (5.0±2.5 mm Hg in CYP3A4 poor/intermediate metabolizers compared with 4.1±2.1 mm Hg in controls, P=0.327). Family history of glaucoma was similar in both groups (7/22 vs. 8/22, P=1.0). Conclusion: Reduced CYP3A4 phenotypes may help identify patients at a higher risk of steroid-induced IOP elevation.
ARGONAUT-III and -V: susceptibility of carbapenem-resistant Klebsiella pneumoniae and multidrug-resistant Pseudomonas aeruginosa to the bicyclic boronate β-lactamase inhibitor taniborbactam comb
Jacobs, Michael R. , Abdelhamed, Ayman M., Good, Caryn E., Mack, Andrew R , Bethel, Christopher R. , Marshall, Steven H. , Hujer, Andrea M. , Hujer, Kristine M., Patel, Robin , Fowler, Vance G. , Rhoads, Daniel D. , Six, David A. , Uehara, Tsuyoshi , Papp‐Wallace, Krisztina M. , van Duin, David , Rhoads, Daniel D , Six, David A , Moeck, Greg , Uehara, Tsuyoshi , Papp-Wallace, Krisztina M , Bonomo, Robert A , Patel, Robin , Fowler, Vance G. , Bonomo, Robert A.

Mayo Clinic

Antimicrobial Agents and Chemotherapy | August 12, 2024 | Volume: 68 | Issue: 9 | Pages: No page available

10.1128/aac.00751-24 | PMID 39133021 Get It

ABSTRACT Taniborbactam, a bicyclic boronate β-lactamase inhibitor with activity against Klebsiella pneumoniae carbapenemase (KPC), Verona integron–encoded metallo-β-lactamase (VIM), New Delhi metallo-β-lactamase (NDM), extended-spectrum beta-lactamases (ESBLs), OXA-48, and AmpC β-lactamases, is under clinical development in combination with cefepime. Susceptibility of 200 previously characterized carbapenem-resistant K. pneumoniae and 197 multidrug-resistant (MDR) Pseudomonas aeruginosa to cefepime-taniborbactam and comparators was determined by broth microdilution. For K. pneumoniae (192 KPC; 7 OXA-48-related), MIC 90 values of β-lactam components for cefepime-taniborbactam, ceftazidime-avibactam, and meropenem-vaborbactam were 2, 2, and 1 mg/L, respectively. For cefepime-taniborbactam, 100% and 99.5% of isolates of K. pneumoniae were inhibited at ≤16 mg/L and ≤8 mg/L, respectively, while 98.0% and 95.5% of isolates were susceptible to ceftazidime-avibactam and meropenem-vaborbactam, respectively. For P. aeruginosa , MIC 90 values of β-lactam components of cefepime-taniborbactam, ceftazidime-avibactam, ceftolozane-tazobactam, and meropenem-vaborbactam were 16, >8, >8, and >4 mg/L, respectively. Of 89 carbapenem-susceptible isolates, 100% were susceptible to ceftolozane-tazobactam, ceftazidime-avibactam, and cefepime-taniborbactam at ≤8 mg/L. Of 73 carbapenem-intermediate/resistant P. aeruginosa isolates without carbapenemases, 87.7% were susceptible to ceftolozane-tazobactam, 79.5% to ceftazidime-avibactam, and 95.9% and 83.6% to cefepime-taniborbactam at ≤16 mg/L and ≤8 mg/L, respectively. Cefepime-taniborbactam at ≤16 mg/L and ≤8 mg/L, respectively, was active against 73.3% and 46.7% of 15 VIM- and 60.0% and 35.0% of 20 KPC-producing P. aeruginosa isolates. Of all 108 carbapenem-intermediate/resistant P. aeruginosa isolates, cefepime-taniborbactam was active against 86.1% and 69.4% at ≤16 mg/L and ≤8 mg/L, respectively, compared to 59.3% for ceftolozane-tazobactam and 63.0% for ceftazidime-avibactam. Cefepime-taniborbactam had in vitro activity comparable to ceftazidime-avibactam and greater than meropenem-vaborbactam against carbapenem-resistant K. pneumoniae and carbapenem-intermediate/resistant MDR P. aeruginosa .
International Headache Society global practice recommendations for the acute pharmacological treatment of migraine
Puledda, Francesca , Diener, Hans‐Christoph , Al‐Khazali, Haidar M. , Ashina, Sait , Liebler, Eric , Chu, Min Kyung , Cocores, Alexandra, Dodd-Glover, Freda , Ekizoğlu, Esme , Göbel, Carl, Hassan, Amr , Hirata, Koichi , Hoffmann, Jan , Jenkins, Bronwyn , Kamm, Katharina , Martinelli, Daniele , Monteith, Teshamae , Romanenko, V.I. , Vandenbussche, Nicolas , Tassorelli, Cristina , Diener, Hans-Christoph , Ashina, Sait , Chu, Min Kyung , Garcia-Azorin, David , Hoffmann, Jan , Kamm, Katharina , Lee, Mi Ji , Ling, Yu-Hsiang , Martinelli, Daniele , Monteith, Teshamae S , Ornello, Raffaele , Rozen, Todd D. , Pozo-Rosich, Patricia , Souza, Marcio Nattan P , Thuraiaiyah, Janu , Togha, Mansoureh , Wang, Shuu-Jiun , Yu, Shengyuan , Tassorelli, Cristina , Al-Khazali, Haidar M , Puledda, Francesca , Hassan, Amr , Sacco, Simona , Ashina, Messoud , Burstein, Rami , Cipriani, Andrea , Göbel, Carl Hartmut , Goicochea, María Teresa , Lee, Mi Ji , Lisicki, Marco , Ornello, Raffaele , Özge, Aynur , Peres, Mário Fernando Prieto , Pozo‐Rosich, Patricia , Schwedt, Todd J. , Takizawa, Tsubasa , Terwindt, Gisela M. , Wang, Shuu‐Jiun

Mayo Clinic

Cephalalgia | August 12, 2024 | Volume: 44 | Issue: 8 | Pages: No page available

10.1177/03331024241252666 | PMID 39133176 Get It

Background In an effort to improve migraine management around the world, the International Headache Society (IHS) has here developed a list of practical recommendations for the acute pharmacological treatment of migraine. The recommendations are categorized into optimal and essential, in order to provide treatment options for all possible settings, including those with limited access to migraine medications. Methods An IHS steering committee developed a list of clinical questions based on practical issues in the management of migraine. A selected group of international senior and junior headache experts developed the recommendations, following expert consensus and the review of available national and international headache guidelines and guidance documents. Following the initial search, a bibliography of twenty-one national and international guidelines was created and reviewed by the working group. Results A total of seventeen questions addressing different aspects of acute migraine treatment have been outlined. For each of them we provide an optimal recommendation, to be used whenever possible, and an essential recommendation to be used when the optimal level cannot be attained. Conclusion Adoption of these international recommendations will improve the quality of acute migraine treatment around the world, even where pharmacological options remain limited.
Dopamine Pathway and Parkinson's Risk Variants Are Associated with Levodopa‐Induced Dyskinesia
Sosero, Yuri L. , Bandrés‐Ciga, Sara , Tocino, Maria Teresa Periñan, Belloso, Dìaz R., Gómez‐Garre, Pilar , Faouzi, Johann , Pavelka, Lukas , Marques, Tainá M. , May, Patrick , Milanowski, Łukasz , Uitti, Ryan J. , Hilten, Jacobus J. van , Simon, David K. , Eberly, Shirley , Krohn, Lynne , Freeman, Kathryn , Ruskey, Jennifer A. , Asayesh, Farnaz , Menéndez‐González, Manuel , Pástor, Pau , Ross, Owen A. , Krüger, Rejko , Kõks, Sulev, Mir, Pablo , Klucken, Jochen , Gómez‐Garre, Pilar , Fatima, Noor , Gómez-Garre, Pilar , May, Patrick , Milanowski, Łukasz M , Wszolek, Z.K. , Simon, David K , Ross, Owen A , Corvol, Jean-Christophe , Koks, Sulev , Mir, Pablo , de Bie, Rob M A , Iwaki, Hirotaka , Gan-Or, Ziv , Pastor, Pau , Ferwerda, Bart , Taba, Pille , Gomes, Clarissa P. C. , Kolodkin, Alexey N. , Wszołek, Zbigniew K. , Heutink, Peter , Álvarez, Ignacio , Yu, Eric , Freeman, Kathryn, Rudakou, Uladzislau , Corvol, Jean‐Christophe , Bie, Rob M.A. de , Gan‐Or, Ziv

Mayo Clinic

Movement Disorders | August 12, 2024 | Volume: 39 | Issue: 10 | Pages: 1773-1783

10.1002/mds.29960 | PMID 39132902 Get It

Abstract Background Levodopa‐induced dyskinesia (LID) is a common adverse effect of levodopa, one of the main therapeutics used to treat the motor symptoms of Parkinson's disease (PD). Previous evidence suggests a connection between LID and a disruption of the dopaminergic system as well as genes implicated in PD, including GBA1 and LRRK2 . Objectives Our goal was to investigate the effects of genetic variants on risk and time to LID. Methods We performed a genome‐wide association study (GWAS) and analyses focused on GBA1 and LRRK2 variants. We also calculated polygenic risk scores (PRS) including risk variants for PD and variants in genes involved in the dopaminergic transmission pathway. To test the influence of genetics on LID risk we used logistic regression, and to examine its impact on time to LID we performed Cox regression including 1612 PD patients with and 3175 without LID. Results We found that GBA1 variants were associated with LID risk (odds ratio [OR] = 1.65; 95% confidence interval [CI], 1.21–2.26; P = 0.0017) and LRRK2 variants with reduced time to LID onset (hazard ratio [HR] = 1.42; 95% CI, 1.09–1.84; P = 0.0098). The fourth quartile of the PD PRS was associated with increased LID risk (OR fourth_quartile = 1.27; 95% CI, 1.03–1.56; P = 0.0210). The third and fourth dopamine pathway PRS quartiles were associated with a reduced time to development of LID (HR third_quartile = 1.38; 95% CI, 1.07–1.79; P = 0.0128; HR fourth_quartile = 1.38; 95% CI = 1.06–1.78; P = 0.0147). Conclusions This study suggests that variants implicated in PD and in the dopaminergic transmission pathway play a role in the risk/time to develop LID. Further studies will be necessary to examine how these findings can inform clinical care. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Creation of a predictive calculator to determine adequacy of occlusion of the woven endobridge (WEB) device in intracranial aneurysms—A retrospective analysis of the WorldWide WEB Consortium database
Musmar, Basel , Adeeb, Nimer , Gendreau, Julian , Horowitz, Melanie Alfonzo , Salim, Hamza , Sanmugananthan, Praveen , Aslan, Assala , Cancelliere, Nicole M , McLellan, Rachel , Şenol, Yiğit Can , Lay, Sovann V. , Guenego, Adrien , Renieri, Leonardo, Naamani, Kareem El, Premat, Kévin , Möhlenbruch, Markus, Kral, Michael , Doron, Omer , Salem, Mohamed M , Foreman, Paul M. , Vachhani, Jay A. , Shaikh, Hamza , Župančić, Vedran , Tutino, Vincent M. , Gokhan, Yuce, İmamoğlu, Çetin , Rabinov, James D. , Ren, Yifan , Michelozzi, Caterina , Elens, Stéphanie , Starke, Robert M, Ogilvie, Mark , Nguyên, Anh , Jones, Jesse , Brinjikji, Waleed , Nawka, Marie Teresa , Psychogios, Marios, Ulfert, Christian , Diestro, Jose Danilo Bengzon , Pukenas, Bryan , Burkhardt, Jan‐Karl , Martinez-Gutierrez, Juan Carlos, Essibayi, Muhammed Amir , Spiegel, Gary, Lubicz, Boris , Puri, Ajit S., Pero, Guglielmo , Nossek, Erez , Raz, Eytan , Killer-Oberfalzer, Monika, Asadi, Hamed , Brook, Allan , Altschul, David , Ducruet, Andrew F. , Albuquerque, Felipe C. , Regenhardt, Robert W. , Stapleton, Christopher J. , Kan, Peter, Kalousek, Vladimir , Lylyk, Pedro , Boddu, Srikanth , Knopman, Jared , Tjoumakaris, Stavropoula , Clarençon, Frédéric , Bydon, Mohamad , Patel, Aman B. , Salim, Hamza , Algin, Oktay , Ghozy, Sherief , Dibas, Mahmoud , Senol, Yigit Can , Guenego, Adrien , Tjoumakaris, Stavropoula , Shotar, Eimad , Lylyk, Ivan , Foreman, Paul M , Shaikh, Hamza A , Župančić, Vedran , Hafeez, Muhammad U , Ren, Yifan , Schirmer, Clemens M , Hassan, Ameer E , Nguyen, Anh , Jones, Jesse , Ulfert, Christian , Essibayi, Muhammed Amir , Tawk, Rabih, Pero, Guglielmo , Raz, Eytan , Griessenauer, Christoph J , Siddiqui, Adnan H , Altschul, David J , Regenhardt, Robert W , Limbucci, Nicola , Cuellar-Saenz, Hugo H , Dmytriw, Adam A , Diestro, Jose Danilo B , Tutino, Vincent M , Kalousek, Vladimir , Musmar, Basel , Cancelliere, Nicole M , Lay, Sovann V , Burkhardt, Jan‐Karl , Brown, Nolan J. , Ghozy, Sherief , Dibas, Mahmoud , Orscelik, Atakan , Renieri, Leonardo , Carnevale, Joseph Anthony , Saliou, Guillaume , Mastorakos, Panagiotis , Naamani, Kareem El , Shotar, Eimad , Möhlenbruch, Markus , Chung, Charlotte , Lylyk, Iván , Hafeez, Muhammad Ubaid , Catapano, Joshua S , Waqas, Muhammad , Bayrak, Ahmet , Schirmer, Clemens M. , Piano, Mariangela , Kühn, Anna Luisa , Hassan, Ameer E , Psychogios, Marios‐Nikos , Huynh, Thien , Martinez-Gutierrez, Juan Carlos , Sheth, Sunil A , Tawk, Rabih G. , Panni, Pietro , Puri, Ajit S , Griessenauer, Christoph J. , Siddiqui, Adnan H. , Aziz‐Sultan, Mohammad Ali , Limbucci, Nicola , Hasan, David , Cuellar, Hugo , Jabbour, Pascal , Mendes Pereira, Vitor , Dmytriw, Adam A.

Mayo Clinic

Interventional Neuroradiology | August 10, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/15910199241267320 | PMID 39127463 Get It

Background Endovascular treatment with the woven endobridge (WEB) device has been widely utilized for managing intracranial aneurysms. However, predicting the probability of achieving adequate occlusion (Raymond–Roy classification 1 or 2) remains challenging. Objective Our study sought to develop and validate a predictive calculator for adequate occlusion using the WEB device via data from a large multi-institutional retrospective cohort. Methods We used data from the WorldWide WEB Consortium, encompassing 356 patients from 30 centers across North America, South America, and Europe. Bivariate and multivariate regression analyses were performed on a variety of demographic and clinical factors, from which predictive factors were selected. Calibration and validation were conducted, with variance inflation factor (VIF) parameters checked for collinearity. Results A total of 356 patients were included: 124 (34.8%) were male, 108 (30.3%) were elderly (≥65 years), and 118 (33.1%) were current smokers. Mean maximum aneurysm diameter was 7.09 mm (SD 2.71), with 112 (31.5%) having a daughter sac. In the multivariate regression, increasing aneurysm neck size (OR 0.706 [95% CI: 0.535–0.929], p = 0.13) and partial aneurysm thrombosis (OR 0.135 [95% CI: 0.024–0.681], p = 0.016) were found to be the only statistically significant variables associated with poorer likelihood of achieving occlusion. The predictive calculator shows a c-statistic of 0.744. Hosmer–Lemeshow goodness-of-fit test indicated a satisfactory model fit with a p-value of 0.431. The calculator is available at: https://neurodx.shinyapps.io/WEBDEVICE/ . Conclusion The predictive calculator offers a substantial contribution to the clinical toolkit for estimating the likelihood of adequate intracranial aneurysm occlusion by WEB device embolization.
Communication in the ICU: An Unintended Nocebo Effect?
Guiance, Irene Riestra , Wallace, Lindsey , Hosey, Megan M. , Chitulangoma, Jillene, Philbrick, Kemuel L. , Weiman, Madeline, Schmitt, Emily, Pasko, David, Karnatovskaia, Lioudmila V. , Riestra Guiance, Irene, Niven, Alexander, Hosey, Megan , Philbrick, Kemuel, Karnatovskaia, Lioudmila , Wallace, Lindsey , Varga, Katalin , Niven, Alexander S. , Gajic, Ognjen

Mayo Clinic

Journal of Patient Experience | August 9, 2024 | Volume: 11 | Issue: No issue available | Pages: No page available

10.1177/23743735241272148 | PMID 39130130 Get It

To identify medical phrases utilized by the critical care team that may have an unintended impact on the critically ill patient, we administered an anonymous survey to multi-professional critical care team members. We elicited examples of imprecise language that may have a negative emotional impact on the critically ill. Of the 1600 providers surveyed, 265 offered 1379 examples (912 unique) which were clustered into 5 categories. Medical jargon (eg, “riding the vent”) was most prevalent (n = 549). There were 217 negative suggestions (eg, “you will feel a stick and a burn”). Hyperboles (eg, “black cloud”) were common (n = 198) while homonyms (ie “he fibbed”) accounted for 150 examples. Phrases such as “code brown in there” were categorized as metonyms (n = 144). 121 metaphors/similes (eg, “rearranging deck chairs on the Titanic”) were provided. Phrases that have the potential to negatively impact critically ill patient perceptions are commonplace in critical care practice. Whether these everyday communication habits lead to an unintended nocebo effect on mental health outcomes of the critically ill deserves further study.
Clinical Utility of Protein Language Models in Resolution of Variants of Uncertain Significance in KCNQ1, KCNH2 , and SCN5A Compared With Patch-Clamp Functional C
Ye, Dan , Garmany, Ramin , Martinez-Barrios, Estefania, Gao, Xiaozhi , Neves, Raquel , Tester, David J. , Bains, Sahej , Zhou, Wei , Giudicessi, John R. , Ackerman, Michael J. , Neves, Raquel Almeida Lopes , Bains, Sahej , Ye, Dan , Garmany, Ramin

Mayo Clinic

Circulation: Genomic and Precision Medicine | August 9, 2024 | Volume: 17 | Issue: 5 | Pages: No page available

10.1161/circgen.124.004584 | PMID 39119706 Get It

BACKGROUND: Genetic testing for cardiac channelopathies is the standard of care. However, many rare genetic variants remain classified as variants of uncertain significance (VUS) due to lack of epidemiological and functional data. Whether deep protein language models may aid in VUS resolution remains unknown. Here, we set out to compare how 2 deep protein language models perform at VUS resolution in the 3 most common long-QT syndrome–causative genes compared with the gold-standard patch clamp. METHODS: A total of 72 rare nonsynonymous VUS (9 KCNQ1, 19 KCNH2 , and 50 SCN5A ) were engineered by site-directed mutagenesis and expressed in either HEK293 cells or TSA201 cells. Whole-cell patch-clamp technique was used to functionally characterize these variants. The protein language models, evolutionary scale modeling, version 1b and AlphaMissense, were used to predict the variant effect of missense variants and compared with patch clamp. RESULTS: Considering variants in all 3 genes, the evolutionary scale modeling, version 1b model had a receiver operating characteristic curve–area under the curve of 0.75 ( P =0.0003). It had a sensitivity of 88% and a specificity of 50%. AlphaMissense performed well compared with patch-clamp with an receiver operating characteristic curve-area under the curve of 0.85 ( P <0.0001), sensitivity of 80%, and specificity of 76%. CONCLUSIONS: Deep protein language models aid in VUS resolution with high sensitivity but lower specificity. Thus, these tools cannot fully replace functional characterization but can aid in reducing the number of variants that may require functional analysis.